About
Cognoa is an early childhood development and pediatric behavioral health company on a mission to enable earlier, faster, and more equitable diagnosis of developmental conditions — particularly autism spectrum disorder (ASD). Its flagship product, Canvas Dx, is the first and only FDA-authorized AI-powered diagnostic tool designed to help clinicians diagnose or rule out autism in children ages 18 months to 6 years, delivering results within days rather than the current industry average of a 3-year delay. Canvas Dx uses machine learning and AI to analyze child behavior data collected remotely, overcoming geographic and resource barriers by reducing dependence on scarce, oversubscribed specialty centers. The platform takes a whole-child, objective approach that mitigates prevalent diagnostic biases — girls are currently diagnosed 1.5 years later than boys on average, and underserved minority children are frequently missed altogether. For healthcare professionals, Canvas Dx provides a streamlined clinical workflow with performance metrics and access to clinical research. For families, it shortens the path to answers and appropriate interventions, which are most impactful at the earliest ages. The tool is now reimbursed by Highmark Insurance and has launched its first state Medicaid coverage program in Wyoming, significantly reducing financial barriers. Cognoa serves pediatricians, developmental specialists, healthcare systems, Medicaid programs, and families navigating the autism diagnostic process. It is particularly valuable in rural or underserved areas where specialist access is limited.
Key Features
- FDA-Authorized AI Diagnostic: Canvas Dx is the first and only FDA-authorized AI diagnostic solution for autism, covering children ages 18 months to 6 years.
- Rapid Diagnosis — Days, Not Years: Reduces the average 3-year diagnostic delay to a matter of days, enabling timely early interventions when they matter most.
- Remote Digital Evaluation: Conducts evaluations digitally, eliminating dependence on geographically distant or oversubscribed specialist centers.
- Objective, Bias-Reducing Assessment: Uses data-driven AI to minimize prevalent diagnostic biases that disproportionately affect girls and underserved minority children.
- Insurance & Medicaid Coverage: Reimbursed by Highmark Insurance and the first state Medicaid program (Wyoming), expanding access for underserved populations.
Use Cases
- Pediatricians screening toddlers and preschool-aged children for autism spectrum disorder during well-child visits or developmental concern follow-ups.
- Healthcare systems in rural or underserved areas providing specialist-level autism diagnostics without requiring referrals to distant specialty centers.
- Medicaid programs and insurers integrating a cost-effective, FDA-authorized diagnostic pathway to reduce long-term healthcare costs associated with late autism diagnosis.
- Families of girls or minority children — groups historically diagnosed later or missed entirely — accessing objective, bias-reducing evaluation.
- Clinical researchers studying early childhood developmental conditions using Cognoa's data-driven platform and performance metrics.
Pros
- First FDA-Authorized Solution: Unique regulatory authorization gives clinicians confidence in the diagnostic validity of the AI-driven results.
- Dramatically Faster Time to Diagnosis: Compresses what traditionally takes years into days, enabling earlier access to life-changing interventions.
- Expands Equitable Access: Remote, digital approach serves rural, underserved, and minority communities that are frequently missed by the traditional diagnostic system.
- Growing Insurance Coverage: Active Medicaid and private insurance reimbursement reduces financial barriers for families and healthcare systems.
Cons
- Narrow Age and Condition Scope: Currently focused exclusively on autism diagnosis for children ages 1.5–6; does not yet address broader developmental conditions or older age groups.
- Requires Clinician Prescription: Families cannot self-administer Canvas Dx — access requires a licensed prescriber, which may still be a barrier in some areas.
- Limited Insurance Coverage Geographically: Medicaid reimbursement is currently only live in Wyoming, limiting fully covered access for many Medicaid-dependent families nationwide.
Frequently Asked Questions
What is Canvas Dx?
Canvas Dx is Cognoa's FDA-authorized AI diagnostic tool that enables clinicians to diagnose or rule out autism spectrum disorder in children ages 18 months to 6 years, typically within days.
How does Canvas Dx work?
Canvas Dx collects behavioral data from children via a remote, digital evaluation process. Machine learning models analyze this data to provide clinicians with an objective, data-driven diagnostic output.
Is Canvas Dx covered by insurance?
Yes. Canvas Dx is currently reimbursed by Highmark Insurance and by Wyoming's Medicaid program, with coverage expansion ongoing.
Why is early autism diagnosis important?
Early interventions — ideally before age 4 — have the greatest developmental impact. Late diagnosis costs the healthcare system 2.5x more than an early path to care, and delays mean children miss critical windows for intervention.
Who can use Canvas Dx?
Canvas Dx is designed for licensed clinicians (pediatricians, developmental specialists) who work with children showing developmental concerns. Families can find a Canvas Dx prescriber through Cognoa's website.
